Key result
Pitavastatin plus sitagliptin lowers HbA1c, insulin, cholesterol, and liver enzymes in obese mice.
Why the study?
The effects of co-administration of sitagliptin and pitavastatin on hyperinsulinemia and fatty liver damage in obese mice at preclinical stages of T2DM have not yet been investigated.
Does combination treatment with pitavastatin and sitagliptin improve hyperinsulinemia and fatty liver damage in obese ob/ob mice compared to vehicle?
Does combination treatment with pitavastatin and sitagliptin improve hyperinsulinemia and fatty liver damage in obese ob/ob mice compared to vehicle?
Answers are grounded in this paper and cite their sources.
Combination therapy with sitagliptin and pitavastatin reduced hyperinsulinemia, markers of liver damage, and total cholesterol in an obese mouse model.
Methods AnimalsIn this study, male C57BL/6JHamSlc-+/+ mice and C57BL/6JHamSlc-ob/ob mice (Japan SLC Inc., Shizuoka, Japan) that weighed 18-22 g and 38-42 g (both 7 weeks of age) were used.We used young adult mice for long treatment periods.The mice were maintained on a standard powder diet (MF ® diet; AbstractObesity contributes to the development of insulin resistance and the subsequent incidence of Type 2 Diabetes Mellitus (T2DM).The effects of co-administration of sitagliptin (dipeptidylpeptidase-4 inhibitor) and pitavastatin (lipid-lowering drug) on hyperinsulinemia and fatty liver damage accompanied by obesity in the preclinical stages of T2DM have not yet been investigated.We aimed to evaluate the additive effects of co-administration of sitagliptin and pitavastatin on hyperinsulinemia and fatty liver damage in obese ob/ob mice.Normal male C57BL/6J mice and obese ob/ob mice were divided into four groups, each receiving different drugs: standard mice chow, n = 8 (Normal); ob/ob mice with vehicle, n = 8 (Control); sitagliptin, n=8 (SG); pitavastatin+ sitagliptin, n = 8 (SG + PS).At the end of the study period (8 weeks), blood samples were drawn from all mice to determine Glycated Hemoglobin (HbA1c), serum glucose, insulin, triglyceride, total cholesterol, High-Density Lipoprotein (HDL) cholesterol, Aspartate-Aminotransferase (AST), Alanine Aminotransferase (ALT) and leptin levels.The SG+PS group had significantly (P < 0.05) lower levels of HbA1c, serum insulin, total cholesterol, AST, and ALT, and liver weight ratio, than did the Control group.And also, the SG+PS group had significantly (P < 0.05) higher levels of leptin than did the Control group.Body weight and serum glucose levels in the SG+PS group did not significantly decrease compared to those in the Control group.Serum triglyceride and HDL-cholesterol levels were unchanged among the four groups.These results suggest that combination treatment with sitagliptin plus pitavastatin may be a promising therapeutic approach in the management of T2DM because it has a beneficial effect on the pathophysiological processes of obesity.
No takes yet. Share an insight, caveat, or question.
Yoshihiko Hirotani (2014) studied Hyperinsulinemia and fatty liver damage accompanied by obesity (n=32). Pitavastatin plus sitagliptin vs. Vehicle (Control) and sitagliptin alone was evaluated on Levels of HbA1c, serum glucose, insulin, triglyceride, total cholesterol, HDL cholesterol, AST, ALT, and leptin (p=<0.05). Combination treatment with pitavastatin plus sitagliptin lowered HbA1c, serum insulin, total cholesterol, AST, and ALT compared to control in obese mice.
Synapse has enriched 10 related papers. Consider them for comparative context: